[HTML][HTML] A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

A Puyalto, M Rodríguez-Remírez, I López… - Frontiers in …, 2023 - frontiersin.org
Background Harnessing the anti-tumor immune system response by targeting the program
cell death protein (PD-1) and program cell death ligand protein (PD-L1) axis has been a …

Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC

K Kaira, T Higuchi, I Naruse, Y Arisaka, A Tokue… - European journal of …, 2018 - Springer
Background Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in
patients with previously treated non-small cell lung cancer. However, little is known about …

Predictive value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for PD‐L1 expression in non‐small cell lung cancer: A systematic …

HY Seol, YS Kim, SJ Kim - Thoracic cancer, 2020 - Wiley Online Library
Background The purpose of the current study was to investigate the predictive value of 18F‐
fluorodeoxyglucose positron emission tomography/computed tomography (18F‐FDG …

[PDF][PDF] Association between immunotherapy biomarkers and glucose metabolism from F-18 FDG PET.

BS Kim, J Kang, S Jun, H Kim, K Pak… - European Review for …, 2020 - researchgate.net
OBJECTIVE: To assess associations between parameters derived from F-18
fluorodeoxyglucose (FDG) positron emission tomography (PET) and mRNA expression …

Assessing PD-L1 expression level by radiomic features from PET/CT in nonsmall cell lung cancer patients: an initial result

M Jiang, D Sun, Y Guo, Y Guo, J Xiao, L Wang… - Academic radiology, 2020 - Elsevier
Rationale and Objectives To explore the potential value of radiomic features-derived
approach in assessing PD-L1 expression status in nonsmall cell lung cancer (NSCLC) …

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes

FJ Borm, J Smit, J Bakker, M Wondergem… - …, 2023 - Taylor & Francis
Better biomarkers for programmed death-(ligand) 1 (PD-(L) 1) checkpoint blockade in non-
small cell lung cancer (NSCLC) are needed. We explored the predictive value of early …

[HTML][HTML] Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by 18F-FDG PET/CT Radiomics and Clinicopathological Characteristics

J Li, S Ge, S Sang, C Hu, S Deng - Frontiers in Oncology, 2021 - frontiersin.org
Purpose In the present study, we aimed to evaluate the expression of programmed death-
ligand 1 (PD-L1) in patients with non-small cell lung cancer (NSCLC) by radiomic features of …

[引用][C] Efficacy-predictive biomarkers of anti-PD-1/PD-L1 immunotherapy for non-small cell lung cancer

S ZHAO, T JIANG, C ZHOU - Tumor, 2016

Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy

CG Kim, SH Hwang, KH Kim, HI Yoon… - Therapeutic …, 2022 - journals.sagepub.com
Background: Predictive markers for treatment response and survival outcome have not been
identified in patients with advanced non-small-cell lung cancer (NSCLC) receiving …

[HTML][HTML] Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [68Ga] Ga-NOTA-Nb109

Q Liu, X Wang, Y Yang, C Wang, J Zou… - Quantitative Imaging in …, 2022 - ncbi.nlm.nih.gov
Background Accurate evaluation of programmed death-ligand 1 (PD-L1) expression levels
in cancer patients may be useful in the identification of potential candidates for anti …